Detection of hepatocellular carcinoma using glycomic analysis - PubMed (original) (raw)
Comparative Study
. 2009 Mar 1;15(5):1808-13.
doi: 10.1158/1078-0432.CCR-07-5261. Epub 2009 Feb 17.
Habtom W Ressom, Rency S Varghese, Lenka Goldman, Gregory Bascug, Christopher A Loffredo, Mohamed Abdel-Hamid, Iman Gouda, Sameera Ezzat, Zuzana Kyselova, Yehia Mechref, Milos V Novotny
Affiliations
- PMID: 19223512
- PMCID: PMC2850198
- DOI: 10.1158/1078-0432.CCR-07-5261
Comparative Study
Detection of hepatocellular carcinoma using glycomic analysis
Radoslav Goldman et al. Clin Cancer Res. 2009.
Abstract
Purpose: Hepatocellular carcinoma (HCC) represents an increasing health problem in the United States. Serum alpha-fetoprotein, the currently used clinical marker, is elevated in only approximately 60% of HCC patients; therefore, the identification of additional markers is expected to have significant public health impact. The objective of our study was to quantitatively assess N-glycans originating from serum glycoproteins as alternative markers for the detection of HCC.
Experimental design: We used matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for quantitative comparison of 83 N-glycans in serum samples of 202 participants (73 HCC cases, 77 age- and gender-matched cancer-free controls, and 52 patients with chronic liver disease). N-glycans were enzymatically released from serum glycoproteins and permethylated before mass spectrometric quantification.
Results: The abundance of 57 N-glycans was significantly altered in HCC patients compared with controls. The sensitivity of six individual glycans evaluated for separation of HCC cases from population controls ranged from 73% to 90%, and the specificity ranged from 36% to 91%. A combination of three selected N-glycans was sufficient to classify HCC with 90% sensitivity and 89% specificity in an independent validation set of patients with chronic liver disease. The three N-glycans remained associated with HCC after adjustment for chronic viral infection and other known covariates, whereas the other glycans increased significantly at earlier stages of the progression of chronic viral infection to HCC.
Conclusion: A set of three identified N-glycans is sufficient for the detection of HCC with 90% prediction accuracy in a population with high rates of hepatitis C viral infection. Further evaluation of a wider clinical utility of these candidate markers is warranted.
Conflict of interest statement
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Figures
Fig. 1
Average MALDI-TOF spectra in the mass range of 1.5 to 5.5 kDa in HCC cases (n = 73) and population controls (n = 77; inverted).
Fig. 2
Area under the ROC curve (AuROC) for three glycans comparing a blinded validation set of HCC cases (n = 47) and CLD controls (n = 27).
Fig. 3
Box plots comparing three selected glycans in the following patient groups: fibrosis (n = 22; A), cirrhosis (n = 25; B), and early HCC (stage I and II; n = 18; C). Both the fibrosis and cirrhosis groups are significantly different from the early-stage HCC at P < 0.05 as indicated in the figure.
Similar articles
- Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches.
Zhu J, Warner E, Parikh ND, Lubman DM. Zhu J, et al. Mass Spectrom Rev. 2019 May;38(3):265-290. doi: 10.1002/mas.21583. Epub 2018 Nov 25. Mass Spectrom Rev. 2019. PMID: 30472795 Free PMC article. Review. - Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma.
Ressom HW, Varghese RS, Goldman L, An Y, Loffredo CA, Abdel-Hamid M, Kyselova Z, Mechref Y, Novotny M, Drake SK, Goldman R. Ressom HW, et al. J Proteome Res. 2008 Feb;7(2):603-10. doi: 10.1021/pr0705237. Epub 2008 Jan 12. J Proteome Res. 2008. PMID: 18189345 Free PMC article. - Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum.
Goldman R, Ressom HW, Abdel-Hamid M, Goldman L, Wang A, Varghese RS, An Y, Loffredo CA, Drake SK, Eissa SA, Gouda I, Ezzat S, Moiseiwitsch FS. Goldman R, et al. Carcinogenesis. 2007 Oct;28(10):2149-53. doi: 10.1093/carcin/bgm177. Epub 2007 Aug 27. Carcinogenesis. 2007. PMID: 17724376 Free PMC article. - Analysis of MALDI-TOF mass spectrometry data for detection of glycan biomarkers.
Ressom HW, Varghese RS, Goldman L, Loffredo CA, Abdel-Hamid M, Kyselova Z, Mechref Y, Novotny M, Goldman R. Ressom HW, et al. Pac Symp Biocomput. 2008:216-27. Pac Symp Biocomput. 2008. PMID: 18229688 Free PMC article. - Natural history of chronic hepatitis B REVEALed.
Chen CJ, Yang HI. Chen CJ, et al. J Gastroenterol Hepatol. 2011 Apr;26(4):628-38. doi: 10.1111/j.1440-1746.2011.06695.x. J Gastroenterol Hepatol. 2011. PMID: 21323729 Review.
Cited by
- Examination of glycan profiles from IgG-depleted human immunoglobulins facilitated by microscale affinity chromatography.
Svoboda M, Mann BF, Goetz JA, Novotny MV. Svoboda M, et al. Anal Chem. 2012 Apr 3;84(7):3269-77. doi: 10.1021/ac203336u. Epub 2012 Mar 13. Anal Chem. 2012. PMID: 22360417 Free PMC article. - Delineating diseases by IMS-MS profiling of serum N-linked glycans.
Isailovic D, Plasencia MD, Gaye MM, Stokes ST, Kurulugama RT, Pungpapong V, Zhang M, Kyselova Z, Goldman R, Mechref Y, Novotny MV, Clemmer DE. Isailovic D, et al. J Proteome Res. 2012 Feb 3;11(2):576-85. doi: 10.1021/pr200777u. Epub 2011 Dec 30. J Proteome Res. 2012. PMID: 22148953 Free PMC article. - Glycan Node Analysis: A Bottom-up Approach to Glycomics.
Zaare S, Aguilar JS, Hu Y, Ferdosi S, Borges CR. Zaare S, et al. J Vis Exp. 2016 May 22;(111):53961. doi: 10.3791/53961. J Vis Exp. 2016. PMID: 27284957 Free PMC article. - Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches.
Zhu J, Warner E, Parikh ND, Lubman DM. Zhu J, et al. Mass Spectrom Rev. 2019 May;38(3):265-290. doi: 10.1002/mas.21583. Epub 2018 Nov 25. Mass Spectrom Rev. 2019. PMID: 30472795 Free PMC article. Review. - N-glycan profiling by microchip electrophoresis to differentiate disease states related to esophageal adenocarcinoma.
Mitra I, Zhuang Z, Zhang Y, Yu CY, Hammoud ZT, Tang H, Mechref Y, Jacobson SC. Mitra I, et al. Anal Chem. 2012 Apr 17;84(8):3621-7. doi: 10.1021/ac203431s. Epub 2012 Apr 3. Anal Chem. 2012. PMID: 22397697 Free PMC article.
References
- Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LAM. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2003;963:13–20. - PubMed
- El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States [see comments] N Engl J Med. 1999;340:745–50. - PubMed
- Ezzat S, Abdel-Hamid M, Eissa SA, et al. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health. 2005;208:329–39. - PubMed
- Perz JF, Alter MJ. The coming wave of HCV-related liver disease: dilemmas and challenges. J Hepatol. 2006;44:441–3. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R03 CA119288/CA/NCI NIH HHS/United States
- U01 CA168926/CA/NCI NIH HHS/United States
- R01 CA135069/CA/NCI NIH HHS/United States
- R01 CA085888/CA/NCI NIH HHS/United States
- R01 CA135069-01A1/CA/NCI NIH HHS/United States
- RR018942/RR/NCRR NIH HHS/United States
- R01 CA115625/CA/NCI NIH HHS/United States
- R01 CA115625-01A2/CA/NCI NIH HHS/United States
- P41 RR018942/RR/NCRR NIH HHS/United States
- R01CA85888/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical